The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 (2020)

Peer-Reviewed Study · Schmith VD, Zhou JJ, Lohmer LRL (Nuventra Pharma Sciences) · October 2020

Schmith VD et al., 2020-10: Pharmacometric modelling paper showing that oral ivermectin at the approved dose, and at 10 times it, does not reach the in-vitro inhibitory concentrations used in the laboratory.

Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC50 in the lungs after single oral administration of the approved dose

Schmith VD et al., 2020-10: Pharmacometric modelling paper showing that oral ivermectin at the approved dose, and at 10 times it, does not reach the in-vitro inhibitory concentrations used in the laboratory. C6. Study type: population-PK modelling (no new subjects), using an available population pharmacokinetic model. Country: USA (Nuventra Pharma Sciences, Durham NC). Numbers as published: in-vitro IC50 2 uM was '>35x higher than the maximum plasma concentration (Cmax) after oral administration of the approved dose'; predicted lung Cmax 0.0873 uM at the approved dose and 0.820 uM at 10x the approved dose. Funder/conflicts: authors are consultants who state they 'have not worked with companies who produce ivermectin orally (EDENBRIDGE PHARMS and MERCK)' and 'declared no competing interests for this work'. Product modelled: oral ivermectin. Comparator: none (simulation). The paper's conclusion concerns COVID-19 dosing, but the PK arithmetic is drug-level and applies to any indication requiring micromolar exposure. Study type: other.